Your Thyroid Problem Is Actually A Conversion Problem

Your thyroid makes a hormone called T4, which is mostly inactive, and your body is supposed to convert it into T3, which is the version your cells actually use to regulate metabolism, energy, body temperature, and about a hundred other things you feel every day.

That conversion does not happen in your thyroid. Between 70 and 90 percent of your active T3 is made in peripheral tissues, meaning your liver, your kidneys, and your skeletal muscle. The thyroid itself contributes a smaller fraction. So your thyroid is essentially a raw material supplier, and the real manufacturing happens downstream.

That distinction matters more than most people realize, and almost all thyroid treatment ignores it.

The mechanism behind conversion is a family of enzymes called deiodinases, which are proteins that strip iodine atoms off of T4 to activate it or deactivate it depending on which atom gets removed. Type 1 deiodinase, called D1, is concentrated in the liver and kidneys. Type 2 deiodinase, called D2, is found heavily in skeletal muscle. Both of these convert T4 into active T3. There is also a Type 3 deiodinase that converts T4 into something called reverse T3, which is the inactive mirror image of T3 that blocks your receptors without activating them.

So you have a gas pedal and a brake built into the same system, and the balance between active T3 and reverse T3 determines how much of that fuel your cells actually use.

Here is where the standard model starts to break down. Most doctors check a number called TSH, which stands for thyroid stimulating hormone, and TSH is released by your pituitary gland to signal the thyroid to make more T4. When TSH is in range, the standard interpretation is that everything is fine. But TSH only tells you what the pituitary is seeing. It tells you nothing about what is happening at the conversion step, and it tells you nothing about whether the T3 your cells are actually receiving is adequate.

A 2011 study published in PLoS ONE looked at patients who had their thyroid completely removed and were given standard levothyroxine replacement, which is synthetic T4. Even when their TSH was normalized, more than 20 percent of those patients still had abnormal free T3 or free T4 levels. Their pituitary was satisfied, but their cells were not getting what they needed. The TSH looked fine and the patient still felt terrible, and by the standard model, nothing was wrong.

That gap between TSH and actual cell-level T3 availability is what most thyroid treatment is missing.

The question is what disrupts conversion in the first place.

Chronic stress is one of the most direct inputs. High cortisol suppresses D1 and D2 activity and shifts the system toward producing more reverse T3 instead of active T3. This is partly adaptive, because during genuine physical threat your body does not want to run a high metabolic rate, but in people under chronic low-grade stress this becomes a persistent suppression that looks on labs like a functional thyroid problem even when the gland itself is perfectly healthy.

Inadequate protein is another major lever. The deiodinase enzymes require amino acids to function, selenium is a required cofactor for all three deiodinase types, and without adequate dietary protein coming in, the enzymatic machinery that does conversion degrades. A 2025 case report in Cureus documented a patient with Hashimoto's thyroiditis who substantially improved her thyroid antibody levels and symptom load through a structured high-protein dietary intervention without changing her medication. One case is not proof of a mechanism, but it is consistent with what the enzyme biology would predict.

Muscle mass is a related piece of the puzzle. Because D2 is expressed heavily in skeletal muscle, the more muscle tissue you carry, the more conversion capacity your body has. A larger factory can produce more output from the same raw material. A 2025 cross-sectional study in Biomolecules found that recreational exercise was associated with reduced inflammatory markers in Hashimoto's patients, which points toward another pathway as well, since inflammation independently suppresses deiodinase activity.

This creates a compounding problem. Low protein intake leads to less muscle. Less muscle means less D2 activity. Less D2 means less T3. Lower T3 slows metabolism further, which makes building muscle harder, which reduces conversion capacity even more.

The standard intervention for hypothyroidism is a drug called levothyroxine, which replaces T4. This makes sense if the problem is a thyroid that is not producing enough raw material. But if the problem is that conversion is impaired, adding more T4 does not move you past the broken step. You are piling more fuel in front of a blocked engine.

For patients whose TSH normalizes on levothyroxine but who still have symptoms, some clinicians now add a small amount of liothyronine, which is synthetic T3, to bypass the conversion step entirely and deliver active hormone directly. A 2022 randomized trial published in Frontiers in Endocrinology found that female hypothyroid patients with residual symptoms on levothyroxine reported meaningful improvements in quality of life when T3 was added to their treatment. It is worth noting that the debate around combination therapy is not fully settled in the guidelines, and the American Thyroid Association currently recommends TSH monitoring without routine free T3 or reverse T3 testing, though a growing body of clinical evidence and criticism is pushing against that position.

The hierarchy of what to address matters though. T3 supplementation without fixing the upstream inputs that are breaking conversion is treating the symptom of the broken system rather than the system itself. Cortisol management, protein intake, sleep, resistance training, and adequate selenium all directly support the conversion machinery, and fixing those inputs can move thyroid labs and symptoms in patients who were told their numbers were normal.

The number your doctor is watching is a signal from your brain to your throat. It is not a measure of what your cells are receiving. And the gap between those two things is where most thyroid problems actually live.

---

References

1. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. (2011). Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. PLoS ONE 6(8):e22552. PMC3148220.
2. Cited for: the >20% of patients with abnormal FT3 or FT4 despite normal TSH on levothyroxine.
3. Limbaugh SL, Ennessy LA, Davis KS, Allen VT. (2025). Nutrition Based, High Protein Adjunct Therapy for Hashimoto's Thyroiditis: A Case Report. Cureus 17(9):e91597. PMC12495900.
4. Cited for: protein protocol resolving Hashimoto's symptoms.
5. Vuletić M, Žnidar V, Barić Žižić A, et al. (2025). Recreational Exercise and Inflammatory Patterns in Hashimoto's Thyroiditis: Observations from a Cross Sectional Study. Biomolecules 15(11):1510. PMC12650045.
6. Cited for: exercise reducing inflammatory markers in Hashimoto's patients.
7. Bjerkreim BA, Hammerstad SS, Gulseth HL, et al. (2022). Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy. Frontiers in Endocrinology 13:816566. PMC8902821.
8. Cited for: clinical evidence that adding T3 improves quality of life in patients with residual symptoms.
9. Lindner HH. (2025). Clinical thyroidology: beyond the 1970s' TSH T4 Paradigm. Frontiers in Endocrinology 16:1529791. PMC12234311.
10. Cited for: critique of the TSH only diagnostic model. Note: single author opinion piece.
11. European Thyroid Journal. Role of hepatic deiodinases in thyroid hormone homeostasis. PMC10160546.
12. Cited for: D1 distribution in liver and kidney, D2 distribution in skeletal muscle.
13. ScienceDirect Topics. Thyroxine Deiodinase.
14. Cited for: the 70-90 percent peripheral conversion figure.
15. Pituitary Foundation. Hormone Replacement Medication Interactions.
16. Cited for: thyroid hormone status affecting IGF-1 levels.
17. American Thyroid Association Guidelines on Treatment of Hypothyroidism.
18. Cited for: current guideline recommending TSH for monitoring without routine FT3 or rT3 testing.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness